Format

Send to

Choose Destination
Clin Liver Dis. 2019 Aug;23(3):511-519. doi: 10.1016/j.cld.2019.04.011. Epub 2019 Jun 6.

Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.

Author information

1
Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia; University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia. Electronic address: j.sasadeusz@mh.org.au.
2
Olivia Newton John Cancer Research Institute, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia.
3
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia.
4
National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore.
5
University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia.
6
University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia.
7
St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia.
8
University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA.
9
Ingham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australia.
10
Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia; Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia.
11
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia; Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia.
12
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia.
13
The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia; Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia.
14
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia.
15
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA.

Abstract

Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell-active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.

KEYWORDS:

Cancer; Hematological malignancy; Hepatitis B; Prophylaxis; Reactivation; Rituximab; Solid tumors

PMID:
31266624
DOI:
10.1016/j.cld.2019.04.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center